title: Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis.
abstract: BACKGROUND
  To assess the predictive role of lactate dehydrogenases (LDH) and fibrinogen (FBG) serum levels in metastatic colorectal cancer (mCRC) patients receiving a first-line bevacizumab-based therapy.
  
  
  OBJECTIVE
  The aim of the present analysis was to retrospectively evaluate the role of basal and post-treatment LDH and FBG serum levels in predicting the clinical outcome of 139 mCRC patients receiving first-line chemotherapy in combination with bevacizumab.
  
  
  RESULTS
  A statistically significant association between high pre-treatment LDH and FBG levels and progressive disease was observed with respect to low basal LDH and FBG patients. Furthermore, median progression-free survival was 7.3 versus 10.8 months and 7.3 versus 9.4 months for high and low LDH and FBG levels, respectively. Within the high LDH group, we observed a statistically significant reduction of LDH mean value compared with pre-treatment values in patients with objective response rate and stable disease.
  
  
  CONCLUSIONS
  High LDH and FBG levels correlated with prognosis. A significant correlation between bevacizumab-based chemotherapy-induced reduction in LDH serum levels and response to treatment was observed within the high LDH group. These results, if confirmed in larger prospective studies, could be helpful for early identification of patients responsive to bevacizumab-based chemotherapy or candidate to more aggressive treatments.
authors.affiliation: National Cancer Institute "Giovanni Paolo II", Medical Oncology Unit , Viale Orazio Flacco, 65, 70124 Bari , Italy +39 0805555419 ; +39 0805555419 ; n.silvestris@oncologico.bari.it.
authors.forename: Nicola
authors.initials: N
authors.lastname: Silvestris
authors.forename: Mario
authors.initials: M
authors.lastname: Scartozzi
authors.forename: Giusi
authors.initials: G
authors.lastname: Graziano
authors.forename: Daniele
authors.initials: D
authors.lastname: Santini
authors.forename: Vito
authors.initials: V
authors.lastname: Lorusso
authors.forename: Evaristo
authors.initials: E
authors.lastname: Maiello
authors.forename: Sandro
authors.initials: S
authors.lastname: Barni
authors.forename: Saverio
authors.initials: S
authors.lastname: Cinieri
authors.forename: Fotios
authors.initials: F
authors.lastname: Loupakis
authors.forename: Salvatore
authors.initials: S
authors.lastname: Pisconti
authors.forename: Anna Elisabetta
authors.initials: AE
authors.lastname: Brunetti
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Palasciano
authors.forename: Vincenzo Ostilio
authors.initials: VO
authors.lastname: Palmieri
authors.forename: Michela
authors.initials: M
authors.lastname: Del Prete
authors.forename: Emanuela
authors.initials: E
authors.lastname: Dell'Aquila
authors.forename: Tiziana Pia
authors.initials: TP
authors.lastname: Latiano
authors.forename: Fausto
authors.initials: F
authors.lastname: Petrelli
authors.forename: Stefania
authors.initials: S
authors.lastname: Lutrino
authors.forename: Daniele
authors.initials: D
authors.lastname: Rossini
authors.forename: Riccardo
authors.initials: R
authors.lastname: Giampieri
authors.forename: Claudio
authors.initials: C
authors.lastname: Lotesoriere
authors.forename: Stefano
authors.initials: S
authors.lastname: Cascinu
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D005340:Fibrinogen / Q000032:analysis*; D006801:Humans; D045022:Lactate Dehydrogenases / Q000097:blood*; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005340:Fibrinogen; D045022:Lactate Dehydrogenases
keywords: bevacizumab; clinical outcome; colorectal carcinoma; fibrinogen; lactate dehydrogenases